← 返回前沿论文

人源化 ROBO1 CAR 整合至 NK 细胞 PD-1 位点对非小细胞肺癌产生协同杀伤肿瘤效应

英文原题:Integration of humanized ROBO1 CAR in PD-1 locus in natural killer cells delivers synergistic tumor-killing effect against non-small cell lung cancer.

PubMed 2025/09/05(内容时间) Cancer Gene Ther Q1 · IF 6.4(JCR 2025)

研究概要

肺癌是全球最常见的癌症,也是癌症相关死亡的主要原因之一,然而非小细胞肺癌(NSCLC)的治疗仍然有限,这是一个临床亟待解决的问题。

中文摘要

肺癌是全球最常见的癌症,也是癌症相关死亡的主要原因之一;然而,非小细胞肺癌(NSCLC)的治疗选择仍有限,是临床亟待解决的问题。ROBO1是肿瘤细胞上的重要表面受体,但靶向ROBO1的人源化嵌合抗原受体(CAR)修饰自然杀伤(NK)细胞治疗NSCLC的作用鲜有研究。此外,PD-1在NK细胞杀伤肿瘤细胞中的作用仍有争议。本研究通过检索生物信息数据库,确定ROBO1在肺鳞状细胞癌(LUSC)中的表达模式。我们构建hROBO1-CAR-NK-92细胞并进行功能鉴定;随后将hROBO1-CAR序列插入PD-1基因位点,并开展体内外功能检测。结果显示,ROBO1在LUSC中显著上调。在PD-1位点插入hROBO1-CAR序列后,PD-1敲除的hROBO1-CAR-NK-92细胞具有最佳长期杀伤能力和细胞因子分泌能力,并在小鼠异种移植模型中显著抑制肿瘤生长。我们还观察到,敲除PD-1可抑制细胞衰老,促成PD-1敲除hROBO1-CAR-NK-92细胞的长期杀伤能力。本研究提出ROBO1是NSCLC CAR-NK治疗的重要靶点,并将hROBO1 CAR整合至NK细胞PD-1位点,从而对NSCLC产生协同杀伤效应,为实体瘤治疗提供新策略。

展开英文摘要原文

Lung cancer is the most common cancer and one of the leading causes of cancer-related deaths in the world, however, the treatment of non-small cell lung cancer (NSCLC) is still limited, and it is a clinically urgent problem. ROBO1 is an important surface receptor on tumor cells, but the role of humanized chimeric antigen receptor (CAR) modified natural killer (NK) cells targeting ROBO1 in NSCLC is rarely explored. Furthermore, the role of PD-1 in NK cell killing tumor cells remains controversial. In this study, we identified the expression pattern of ROBO1 in lung squamous cell carcinoma (LUSC) by searching biological information databases. We constructed hROBO1-CAR-NK-92 cells and performed functional identification.We inserted the hROBO1-CAR at the PD-1 locus and performed functional detection in vitro and in vivo. The results showed that ROBO1 expression was significantly increased in LUSC. After inserting the hROBO1-CAR sequence at the PD-1 locus, the PD-1-KO-hROBO1-CAR-NK-92 cells had the best long-term killing ability and cytokine secretion ability, and had a significant inhibitory effect on tumor growth in the mouse xenograft model. We also observed that the long-term killing ability of PD-1-KO-hROBO1-CAR-NK-92 cells was achieved by inhibiting cell senescence via knocking out PD-1. These studies proposed ROBO1 as a key target for CAR-NK therapy in NSCLC and integrated hROBO1 CAR in PD-1 locus in NK cells, resulting in synergistic tumor killing effects in NSCLC, presenting a new treatment strategy for solid tumor treatment.

论文信息

作者
Tao JH、Zhang J、Tang CY、Duan JX、Zhong WJ、Zhang CY、Liu YB、Ling J
第一作者单位
Department of Physiology, Xiangya School of Basic Medical Science, Central South University, Changsha, Hunan, China.China
通讯作者单位
Department of Physiology, Xiangya School of Basic Medical Science, Central South University, Changsha, Hunan, China. guanchaxiang@csu.edu.cn.China
期刊
Cancer gene therapy2025 Nov
原文标识
PubMed 40913086 · DOI 10.1038/s41417-025-00957-x